Q-omics provides the consensus-scored ELOBP3 profile across patient tissues and cancer cell-line models. ELOBP3 expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ELOBP3 is differentially expressed in 4, with the highest sampling consensus in BLCA. Additionally, ELOBP3 RNA expression shows 5,714 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, BLCA, and STAD as cancer lineages where ELOBP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOBP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOBP3 survival associations across molecular data types. ELOBP3 RNA expression shows survival associations in the most cancer types (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOBP3 RNA expression–survival associations across cancer types. High ELOBP3 expression shows unfavorable associations in COAD, SKCM, PRAD, KIRP and READ. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for ELOBP3 RNA expression.
This table summarizes ELOBP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for ELOBP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOBP3 shows lower tumor expression in BLCA, STAD, READ and THCA. The BLCA box plot shows higher ELOBP3 RNA expression in normal versus tumor tissue (log2 FC = −0.417, t-test p = .013).
This table shows molecular features associated with ELOBP3 in patient tissues and cancer cell lines. In patient samples, ELOBP3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
